Pharma BD Deal Intelligence
Article presents the acquisition positively, emphasizing market opportunity and strategic fit: "Gout affects more than eight million Americans, and the…
Takeda divested URL Pharma's non-Colcrys generics business to Sun Pharma's Caraco subsidiary, isolating the branded gout asset and recouping deal cost.
Colchicine binds tubulin and inhibits microtubule polymerization, blunting neutrophil-driven inflammation; Colcrys was approved 2009 with low-dose AGREE-trial…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Takeda America Holdings acquired URL Pharma for $800M upfront plus performance-based contingent earn-outs. Brought Colcrys (only FDA-approved single-ingredient oral colchicine; FY2011 net sales >$430M) into Takeda's gout franchise alongside Uloric. URL's generic business divested to Sun Pharma.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / URL Pharma, Inc. (this deal) | 2012 | $800M | 46 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2012 deals · Takeda Pharmaceutical Company Ltd. deals · Nephrology deals